See more : Guangdong Lingxiao Pump Industry Co.,Ltd. (002884.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of TCR2 Therapeutics Inc. (TCRR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TCR2 Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Apollo Future Mobility Group Limited (0860.HK) Income Statement Analysis – Financial Results
- Sophiris Bio, Inc. (SPHS) Income Statement Analysis – Financial Results
- Edifier Technology Co., Ltd. (002351.SZ) Income Statement Analysis – Financial Results
- Wearable Devices Ltd. (WLDS) Income Statement Analysis – Financial Results
- PropTech Group Limited (PTG.AX) Income Statement Analysis – Financial Results
TCR2 Therapeutics Inc. (TCRR)
About TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.64M | 77.24M | 51.98M | 37.49M | 19.67M | 9.57M | 7.67M |
| General & Administrative | 24.44M | 22.50M | 16.72M | 13.89M | 6.78M | 3.61M | 2.26M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.44M | 22.50M | 16.72M | 13.89M | 6.78M | 3.61M | 2.26M |
| Other Expenses | 30.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 123.08M | 99.74M | 68.70M | 51.38M | 26.45M | 13.18M | 9.93M |
| Cost & Expenses | 123.08M | 99.74M | 68.70M | 51.38M | 26.45M | 13.18M | 9.93M |
| Interest Income | 1.94M | 224.00K | 1.74M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 58.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 63.88M | 2.83M | 1.59M | 862.00K | 419.00K | 298.00K | 220.00K |
| EBITDA | -89.62M | -96.92M | -67.11M | -50.52M | -23.83M | -12.77M | -9.70M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -153.50M | -99.74M | -68.70M | -51.38M | -26.45M | -13.18M | -9.93M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.94M | 224.00K | 1.74M | 3.89M | 2.20M | 110.00K | 15.00K |
| Income Before Tax | -151.56M | -99.52M | -66.96M | -47.50M | -24.25M | -13.07M | -9.92M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 261.00K | 289.00K | 161.00K | 102.00K | 2.20M | 110.00K | 15.00K |
| Net Income | -151.82M | -99.81M | -67.12M | -47.60M | -24.25M | -13.07M | -9.92M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.93 | -2.63 | -2.40 | -2.26 | -1.05 | -2.55 | -1.93 |
| EPS Diluted | -3.93 | -2.63 | -2.40 | -2.26 | -1.05 | -2.55 | -1.93 |
| Weighted Avg Shares Out | 38.63M | 37.94M | 27.99M | 21.10M | 23.19M | 5.13M | 5.13M |
| Weighted Avg Shares Out (Dil) | 38.63M | 37.94M | 27.99M | 21.10M | 23.19M | 5.13M | 5.13M |
TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference
Here's Why TCR2 Therapeutics Inc. (TCRR) is Poised for a Turnaround After Losing 20.2% in 4 Weeks
TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference
TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference
TCRR Stock: Why It Increased Today
TCR² Therapeutics to Host R&D Day on October 20, 2021
TCRR Stock: Why It Significantly Decreased Today
TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors
TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors
TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Source: https://incomestatements.info
Category: Stock Reports